Glioblastoma Multiforme Treatment Market (By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Tumor Treating Field (TTF) Therapy, Immunotherapy; By Drug Class: Temozolomide, Bevacizumab, Lomustine, Carmustine Wafers, Others; By End-use: Hospitals, Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Glioblastoma Multiforme Treatment Market, By Treatment

7.1.  Glioblastoma Multiforme Treatment Market, by Treatment, 2021-2030

7.1.1.    Surgery

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Radiation Therapy

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Chemotherapy

7.1.3.1.        Market Revenue and Forecast (2017-2030)

7.1.4.    Targeted Therapy

7.1.4.1.        Market Revenue and Forecast (2017-2030)

7.1.5.    Tumor Treating Field (TTF) Therapy

7.1.5.1.        Market Revenue and Forecast (2017-2030)

7.1.6.    Immunotherapy

7.1.6.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Glioblastoma Multiforme Treatment Market, By Drug Class

8.1.  Glioblastoma Multiforme Treatment Market, by Drug Class, 2021-2030

8.1.1.    Temozolomide

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    Bevacizumab

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Lomustine

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Carmustine Wafers

8.1.4.1.        Market Revenue and Forecast (2017-2030)

8.1.5.    Others

8.1.5.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Glioblastoma Multiforme Treatment Market, By End User

9.1.  Glioblastoma Multiforme Treatment Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Clinics

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Ambulatory Surgical Centers

9.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Glioblastoma Multiforme Treatment Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.1.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.2.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.3.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.4.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Treatment (2017-2030)

10.5.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Treatment (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Merck & Co., Inc.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Amgen, Inc.

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              F. Hoffmann-La Roche Ltd.

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Pfizer Inc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Amgen, Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Teva Pharmaceutical Industries Ltd.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Sun Pharmaceutical Industries Ltd.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              Arbor Pharmaceuticals, LLC

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Amneal Pharmaceuticals

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Karyopharm Therapeutics, Inc.

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           Sumitomo Dainippon Pharma Oncology, Inc. (Boston Biomedical, Inc.)

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

13.2.              Glossary of Terms

Report Details

  • Report Code:38479
  • Category:Healthcare
  • No. of Pages:150+
  • Format:PDF/PPT/Excel
  • Published:September 2021
  • Historical Year:2021-2022
  • Base Year:2023
  • Estimated Year:2024-2033

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers